While CTL1 can be considered a potential CMT target for glioma therapy, the lack of definitive evidence for abundant expression on bECs in vivo warrants further investigation before it can be validated as a candidate for improving the BBB penetration of therapeutic molecules. This evidence concerns the gene SLC44A1 and central nervous system cancer.